<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00004500 on 2012_04_30: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00004500">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00004500">&#8593; Current version of this study</a></div><h1>View of NCT00004500 on
  2012_04_30</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00004500</td>
</tr>
<tr>
<th>Updated:</th><td>2012_04_30</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Bronchoalveolar Lavage With Lucinactant to Standard Care for the Treatment of the Meconium Aspriation Syndrome (MAS) in Newborn Infants</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>OBJECTIVES:<br>
<br>Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL) in the treatment of meconium aspiration syndrome (MAS) in newborn infants.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>PROTOCOL OUTLINE:<br>
<br>This is a randomized, multicenter study. Patients are randomized to one of two treatment arms.<br>
<br>Arm I: Patients receive lucinactant by bronchoalveolar lavage, into the right and left lung, followed by lung drainage. Treatment repeats when patient stabilizes or every 15 minutes for 2 courses.<br>
<br>Arm II: Patients receive standard treatment including oxygen, conventional mechanical ventilation, sedation, paralysis, vasopressors, and alkalinization.<br>
<br>Patients are followed for 12 months.</p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 3</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Open Label</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Number of Days Receiving Mechanical Ventilation (MV)<br>Time Frame: 28 days<br>Safety Issue? No<br>Description: <p>A patient is not receiving MV if he/she is removed from the mechanical ventilator for &ge; 24 hours. If a patient subsequently requires intubation and MV, the additional time will count as days receiving MV.</p>
</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Incidence of Death<br>Time Frame: 28 days<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Air Leaks<br>Time Frame: 28 days<br>Safety Issue? Yes<br>Description: <p>Includes pulmonary interstitial emphysema (PIE), Pneumothorax, Pneumomediastinium, and Pneumopericardium</p>
</td>
</tr>
<tr>
<th>Condition</th><td>
         Meconium Aspiration
      </td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: Lucinactant      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Experimental</div>
<p>Lucinactant via bronchoaveolar lavage</p>
</td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: Standard Care      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Other</div>
<p>Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization</p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Lucinactant
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: Lucinactant</div>
<p>Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.</p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Other: Standard Care
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: Standard Care</div>
<p>The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC</p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Terminated</td>
</tr>
<tr>
<th>Start date</th><td>
         2000-03
      </td>
</tr>
<tr>
<th>Last follow-up date</th><td>
         2004-11
      
      (Actual)
  </td>
</tr>
<tr>
<th>Primary completion date</th><td>
         2002-11
      
      (Actual)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion Criteria:<br> &nbsp;- Diagnosis of MAS<br> &nbsp;- CMV at time of entry<br> &nbsp;- Enrollment within 48 hours of birth<br> &nbsp;- Gestational age of &ge; 37 weeks<br> &nbsp;- Oxygenation index of &ge; 5 and &le; 30<br> &nbsp;- Written informed consent signed and dated by the infant's parent(s) or legal guardian(s)<br>
<br>Exclusion Criteria:<br> &nbsp;- Congenital anomalies likely to affect any primary or secondary endpoints<br> &nbsp;- Uncontrollable air leaks<br> &nbsp;- Hydrops fetalis<br> &nbsp;- Rupture &ge; 3 weeks of the fetal membranes<br> &nbsp;- Evidence of overwhelming bacterial infection at time of randomization<br> &nbsp;- Markedly labile persistent pulmonary hypertension at time of randomization<br> &nbsp;- Profound neurologic manifestations<br> &nbsp;- Sustained postductal SpOâof &lt; 87% for &ge; 15 minutes at an FiOâof 1.00</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Maximum age</th><td>48 Hours</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Discovery Laboratories</td>
</tr>
<tr>
<th>Organization study ID</th><td>KL4-MAS-03</td>
</tr>
<tr>
<th>Secondary ID</th><td>FD-R-001938
      (US Department of Health and Human Services)
    </td>
</tr>
<tr>
<th>Sponsor</th><td>
               Discovery Laboratories
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Food and Drug Administration
         </td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Results</h2>
</th>
</tr>
<tr>
<td>&nbsp;</td><td>
<p>The Current Version of this study includes results.</p>
</td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
